Clinical trials located in

Reggio Emilia

Reggio Emilia city is located in Italy. Currently, 20 clinical trials are being conducted in this city.

Reggio Emilia, located in Italy’s Emilia-Romagna region, is renowned for its rich history and cultural heritage. Established in 179 BC by the Romans, it boasts numerous medieval structures, including the Basilica of San Prospero and the 16th-century Reggio Emilia Cathedral. The city is also the birthplace of the Italian Tricolor flag, first adopted in 1797. Internationally, Reggio Emilia is celebrated for its innovative approach to early childhood education, known as the Reggio Emilia Approach, emphasizing children’s self-expression, community engagement, and problem-solving skills.

  • CT-EU-00068410

    A study of the treatment of advanced breast cancer with Giredestrant and the drug combination Phesgo

    The study is aimed at patients with locally advanced or metastatic breast cancer that is HER2-positive and ER-positive. HER2 and ER are receptors that can influence the growth of cancer cells. The aim of this study is to evaluate the effectiveness and safety of the combination of giredestrant and Phesgo compared with Phesgo alone after a run-in phase with Phaesgo and taxane-based chemotherapy.

    Phesgo is a combination containing pertuzumab, trastuzumab and hyaluronidase, administered subcutaneously every three weeks. Giredestrant is a capsule taken orally every day. Taxane chemotherapy may include drugs such as Docetaxel and Paclitaxel, which are given intravenously. The aim of the study is to compare how well these drug combinations work in preventing disease progression and improving patient survival.

    • hyaluronidase
    • Giredestrant
    • Pertuzumab
    • Trastuzumab
    • Paclitaxel
    • Docetaxel
  • Study of Palazestrant or standard therapy in advanced ER+/HER2- breast cancer

    This clinical trial is for patients with advanced or metastatic breast cancer with hyperactivity of estrogen receptors (ER+) and no hyperactivity of HER2- receptors (advanced HER2- breast cancer). The therapy used in the study includes a new drug called palazestrant (OP-1250) and other standard endocrine therapies such as Fulvestrant or aromatase inhibitors (anastrozole, letrozole, exemestane).

    The aim of the study is to compare the effectiveness and safety of palazestrant (OP-1250) as monotherapy compared to the above-mentioned standard therapies in the treatment of this type of breast cancer.

    Patients in the study will be randomly assigned to one of the groups – one receiving palazestrant (OP-1250) and the other receiving one of the standard therapies (fulvestrant, anastrozole, letrozole or exemestane). The study will assess progression-free survival (the time from the start of treatment to the time the disease starts to progress again) and overall survival of participants (the time from the start of treatment to death from any cause).

    • Palazestrant
    • Fulvestrant
    • Anastrozole
    • Letrozole
    • Exemestane
  • Testing a new combination therapy with acalabrutinib for a specific type of lymphoma

    This clinical trial is investigating a new combination therapy for diffuse large B-cell lymphoma, a type of lymphoma. The treatment combines Acalabrutinib, a targeted therapy drug, with R-CHOP, a chemotherapy mix consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, a standard chemotherapy regimen. The aim of the study is to evaluate the safety and effectiveness of this combination in improving patient outcomes. It focuses on patients who have not been previously treated for lymphoma. The study aims to find better treatment strategies for this particular type of lymphoma.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Acalabrutinib
    • Cyclophosphamide
    • Rituximab
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    • Pirtobrutinib/LOXO-305
    • Zanubrutinib
    • Ibrutinib
    • Acalabrutinib
  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    • etoposide phosphate
    • oxaliplatin
    • Prednisone
    • Dexamethasone
    • Carboplatin
    • Epcoritamab
    • Ifosfamide
    • Cytarabine
    • Gemcitabine
    • Cyclophosphamide
    • Vincristine
    • Doxorubicin
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Examining long-term use of osimertinib in treating lung cancer

    This study is investigating a drug known as osimertinib. This includes people who have had successful surgery to remove a type of lung cancer called NSCLC. This cancer is caused by a mutation in a protein called EGFR. The aim of this study is to see if osimertinib can prevent the cancer from coming back within 5 years. The goal is also to ensure the drug’s safety for patients. Patients will receive the drug regardless of whether they received chemotherapy after surgery or not. Here are some of the issues investigators in this study will look at: how long it takes for the cancer to come back, if at all; how many people are alive without the disease after 3, 4 and 5 years; and how long people live after starting the drug. Additionally, a key part of the study is monitoring for any potential side effects.

    • Osimertinib
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    • CAPEOX
    • Dostarlimab
    • FOLFOX
  • CT-EU-00041922

    Testing new medication for adult muscle inflammation treatment

    This study aims to test a medicine called Efgartigimod (EFG PH20 SC) for adults who are suffering from a disease called Idiopathic Inflammatory Myopathy (IIM), where muscles become inflamed for unknown reasons. This condition often falls into groups like dermatomyositis, immune-mediated necrotizing myopathy, or specific types of polymyositis. The trial wants to compare how good the medicine is against a placebo. The researchers will look at how much people’s symptoms improve and whether there are any side effects. The test is going to be carried out in many locations and will involve people over 18 years old.

    • Efgartigimod/ EFG PH20 SC
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    • GSK3511294 (Depemokimab)
    • Mepolizumab
    • Benralizumab
  • Comparing treatments in multiple myeloma: talquetamab in combination with other medication

    This study aims to explore the combined effects of talquetamab, daratumumab, pomalidomide, and dexamethasone for treating relapsed or refractory multiple myeloma. One group of patients will receive talquetamab subcutaneous in combination with daratumumab and pomalidomide. The second group will receive talquetamab subcutaneous in combination with daratumumab. The patients of the third group will be treated with daratumumab subcutaneous in combination with pomalidomide and dexamethasone. The research is divided into three phases: screening, treatment, and post-treatment follow-up. The study will assess efficacy, safety, and monitoring various health indicators at specific time points. The results of this combination therapy will be compared to choose the safest and the most effective treatment. The overall duration of the study is expected to be up to 6 years and 6 months.

    • Pomalidomide
    • Talquetamab
    • Dexamethasone
    • Daratumumab
  • Studying repotrectinib effect on advanced solid tumors

    In this trial, the researchers are working on a new medicine called Repotrectinib, targeting people with specific types of advanced solid tumors. This medicine might be most helpful if cancer has certain genetic changes, specifically those called ALK, ROS1, or NTRK1-3. It is an early stage of testing Repotrectinib in two parts or phases. During Phase 1,the researchers are trying to find out what the right dose is. It is important to look at the highest dose that can be given without causing too many side effects, and also the dose makes a difference in how the cancer behaves. This phase will also look at how the medication is processed by the body and how it behaves in the system. The second phase will check how well the medicine works in different groups of people, with some details about their cancer and the treatments they have had in the past. It is important to check if the medicine can shrink the tumors and stop them from growing. The researchers will also measure how long these effects last, how quickly these effects occur.

    • Repotrectinib
  • Exploring magrolimab use for head and neck tumors

    This is a study about treatment of patients with squamous cell carcinoma, a type of head and neck cancer. The study will test the safety and effectiveness of a drug called magrolimab, used together with other cancer treatments. The study wants to know how well the treatment works. Throughout the trial, participants’ health will be closely monitored. This includes regular medical check-ups, imaging tests, and other diagnostic procedures to assess how well the cancer is responding to the treatment regimen.

    • Magrolimab
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Zimberelimab
    • 5-Fluorouracil
    • Docetaxel
  • Testing tulisokibart’s effects on systemic sclerosis related lung disease

    This is a study about the safety and effectiveness of a drug called tulisokibart for people with a specific lung disease often seen in patients with a disease called systemic sclerosis. The lung disease makes it hard for them to breathe because their lung tissues are becoming thick and hard. In this trial, some patients will get tulisokibart and others will get a placebo (a pill without any active medicine). Everyone will be watched closely for any negative reactions, such as unwanted symptoms or health problems. To check how well the drug works, they there will be done a few tests.

    • Tulisokibart
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Researching vamikibart for uveitic macular edema treatments

    The study investigates Vamikibart, a new drug for adults with uveitic macular edema, a condition causing swelling in the eye and vision problems. It tests how well Vamikibart, given as eye injections, can improve vision compared to a sham procedure. The goal is to find a safe, effective treatment for this eye condition, helping people see better and manage their symptoms.

    • Vamikibart
  • Comparing abelacimab and apixaban treatments for blood clots in cancer patients

    This research study is looking at how two different medicines, abelacimab and apixaban, can help people with a severe medical problem called Cancer Associated Thrombosis (CAT). CAT happens when blood clots form inside the veins (a condition called Venous Thromboembolism or VTE) in people with cancer. These blood clots can cause other serious health issues. In this study, the researchers will see if abelacimab (which is given monthly) is as good as apixaban if not better (which you take twice a day every day) for six months. And then look at whether the blood clots come back, if any bleeding happens, and if patients had to stop treatment.

    • Abelacimab
    • Apixaban
  • Comparison of two drugs in the treatment of venous thromboembolism

    The study compares abelacimab and dalteparin in treating blood clot issues in patients with gastrointestinal or genitourinary cancers. It’s open to adults, focusing on those without plans for curative surgery. Abelacimab is given monthly, and dalteparin daily, over six months. It assesses clot recurrence, bleeding risks, and treatment continuation. The goal is to find safer, effective blood clot treatments for cancer patients, improving their care and outcomes.

    • Abelacimab
    • Dalteparin
  • Testing drug combinations in recurring multiple myeloma

    This is a type of research study where the researchers compare two different treatments for multiple myeloma, a type of cancer in your blood. In the study, people will be placed into different groups and receive either a combination of iberdomide, daratumumab, and dexamethasone, or another combination of daratumumab, bortezomib, and dexamethasone. The researchers want to check how well the cancer responds to these treatments and see which one works better.

    • Iberdomide
    • Dexamethasone
    • Bortezomib
    • Daratumumab

See more clinical trials in other cities in Italy:

.